Daily Anesthesiology Research Analysis
Analyzed 168 papers and selected 3 impactful papers.
Summary
Three impactful anesthesiology/critical care studies stood out: a randomized, double-blind trial showing dexmedetomidine reduced postoperative acute kidney injury in elderly orthopedic patients; a British Journal of Anaesthesia methods paper correcting a pH-dependent bias in base excess partitioning for acid–base interpretation; and a large propensity-matched cohort indicating combined inhalation–intravenous anesthesia may be associated with higher 3-year mortality after cancer surgery compared with total intravenous anesthesia.
Research Themes
- Perioperative organ protection and kidney injury prevention
- Methodological advances in acid–base analysis for critical care
- Anesthetic technique and long-term oncologic outcomes
Selected Articles
1. Dexmedetomidine May Reduce the Incidence of Acute Kidney Injury in Elderly Patients Undergoing Orthopedic Surgery: A Randomized, Double-Blind Clinical Trial.
In 295 elderly patients undergoing lower extremity orthopedic surgery, dexmedetomidine reduced AKI within 48 hours from 11.6% to 4.7% (OR 0.37; 95% CI 0.15–0.93) compared with placebo. The regimen (0.4 μg/kg loading, then 0.4 μg/kg/h) was delivered intraoperatively; secondary outcomes included renal biomarkers and in-hospital complications.
Impact: This is a well-designed randomized, double-blind trial demonstrating clinically meaningful renoprotection with dexmedetomidine in a high-risk elderly surgical population.
Clinical Implications: Consider incorporating dexmedetomidine into multimodal anesthesia protocols for elderly orthopedic patients to mitigate early postoperative AKI risk, while monitoring for hemodynamic effects.
Key Findings
- AKI within 48 hours was reduced with dexmedetomidine (4.7%) versus control (11.6%); OR 0.37; 95% CI 0.15–0.93.
- Elderly cohort (mean age 74 years); 295 analyzed from 300 randomized; double-blind, placebo-controlled design.
- Renal biomarkers (cystatin C, eGFR) and in-hospital complications were prespecified secondary outcomes.
Methodological Strengths
- Randomized, double-blind, placebo-controlled design with clear primary endpoint (AKI within 48 hours).
- Standardized dosing regimen and prespecified secondary outcomes including renal biomarkers.
Limitations
- Single-country, single-surgical-domain population; generalizability to other surgeries and settings is uncertain.
- Short primary follow-up window (48 hours) without long-term renal outcome assessment.
Future Directions: Multicenter trials across diverse surgeries to validate renoprotection, define optimal dosing/timing, and assess long-term renal and clinical outcomes.
BACKGROUND: Acute kidney injury (AKI) is a common complication in elderly patients undergoing orthopedic surgery, yet the renoprotective role of dexmedetomidine in this patient population remains unclear. This study aimed to evaluate the effect of dexmedetomidine on the incidence of AKI in elderly patients undergoing lower extremity orthopedic procedures. METHODS: In this randomized, double-blind, placebo-controlled trial, 300 patients aged ≥ 65 scheduled for lower extremity orthopedic surgery were randomized to receive either dexmedetomidine (0.4 μg/kg infused for 10 minutes before induction, followed by 0.4 μg/kg/h until 30 minutes before skin closure) or normal saline (control). The primary outcome was the incidence of AKI within 48 hours postoperatively, based on AKI Network criteria. Secondary outcomes included serum cystatin C and estimated glomerular filtration rate on postoperative day (POD) 1, 2, and 3, in-hospital complications (postoperative nausea and vomiting, delirium, pneumonia, stroke), intensive care unit admission, length of hospital stay, and in-hospital mortality. RESULTS: Of 295 patients who completed the study (62.7% female; mean age, 74 years), AKI occurred in 4.7% (7/149) of the dexmedetomidine group compared with 11.6% (17/146) of the control group (odds ratio = 0.37; 95% CI, 0.15 to 0.93; CONCLUSION: Dexmedetomidine administration was associated with a reduced incidence of AKI in elderly patients undergoing lower extremity orthopedic surgery. The renoprotective effects of dexmedetomidine in this patient population warrant validation in multicenter trials. CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR2400088225).
2. Improving interpretation of metabolic acid-base disorders by correcting pH-dependent bias in base excess partitioning.
This BJA study identifies a clinically relevant pH-dependent systematic error in conventional base excess partitioning and proposes a pH-adjusted sodium approach that markedly improves agreement for estimating unmeasured ions. The method reduces bias and narrows limits of agreement compared with the conventional approach.
Impact: Provides a methodological advance to improve bedside acid–base interpretation, with potential to reduce misestimation of unmeasured ions in critically ill patients.
Clinical Implications: Adopting a pH-adjusted BE partitioning approach may refine detection of unmeasured anions and guide more accurate diagnosis and management of complex metabolic acid–base disorders.
Key Findings
- Conventional BE partitioning exhibited a clinically relevant pH-dependent error with wide limits of agreement (−5.6 to 2.9 mEq/L).
- A novel pH-adjusted [Na+] approach substantially reduced bias and tightened limits of agreement (e.g., around −1.6 to 1.7 mEq/L).
- Improved estimation of unmeasured ions enhances interpretability of metabolic acid–base disorders at the bedside.
Methodological Strengths
- Direct quantitative comparison of conventional versus pH-corrected BE partitioning across pH ranges.
- Clear demonstration of reduced bias and improved agreement for unmeasured ion estimation.
Limitations
- Methodological study without randomized clinical outcome testing; requires external validation in diverse ICU populations.
- Implementation at the bedside may need calculator/EHR integration for routine use.
Future Directions: Validate the pH-adjusted approach across centers and integrate into blood gas analyzers/EHRs; assess whether improved acid–base interpretation translates into better clinical outcomes.
BACKGROUND: Base excess (BE) partitioning is an established tool for bedside interpretation of metabolic acid-base disorders. However, this method assumes that changes in plasma strong ion difference, estimated as [Na METHODS: Unmeasured ions were quantified using conventional BE partitioning and a novel pH-corrected version, in which the [Na RESULTS: The conventional method demonstrated wide limits of agreement (-5.6 to 2.9 mEq L CONCLUSIONS: Conventional base excess partitioning is subject to a clinically relevant pH-dependent error. A variable, pH-adjusted [Na
3. Comparison of total intravenous anesthesia and combined inhalation and intravenous anesthesia on survival after tumor surgery: a propensity score matched cohort study.
In 25,351 cancer surgery patients (PSM cohorts up to 1:3), combined inhalation–intravenous anesthesia (CIVA) was associated with increased 3-year mortality (HR 1.220; 95% CI 1.043–1.404) versus total intravenous anesthesia (TIVA), with no difference in short-term mortality. Findings add to concerns about volatile exposure in oncologic surgery.
Impact: Large-scale, carefully matched cohort addresses a key unanswered question about anesthetic technique and long-term oncologic outcomes, generating a strong hypothesis for prospective trials.
Clinical Implications: When feasible, minimizing volatile anesthetic exposure in oncologic surgery may be prudent until prospective data clarify causality; selection of TIVA versus CIVA should consider tumor biology and adjuvant therapy plans.
Key Findings
- After 1:3 propensity score matching, CIVA was associated with higher 3-year mortality versus TIVA (HR 1.220; 95% CI 1.043–1.404).
- No significant association with short-term (3-month) mortality across matched cohorts.
- Study included 25,351 cancer surgery patients; robustness assessed across multiple matching ratios with Cox models.
Methodological Strengths
- Very large single-center cohort with extensive propensity score matching (1:1, 1:2, 1:3) and multivariable Cox modeling.
- Clear separation of short- versus long-term mortality endpoints.
Limitations
- Retrospective, single-center design susceptible to residual confounding and selection bias.
- Unmeasured oncologic variables (tumor stage, adjuvant therapies) may influence survival independent of anesthetic technique.
Future Directions: Prospective, ideally randomized, trials comparing TIVA vs CIVA in defined cancer types with standardized perioperative oncologic care and long-term follow-up.
BACKGROUND: Prior studies have indicated that inhalation anesthesia in cancer surgery might heighten the risk of tumor metastasis and diminish patient survival. Yet, combined inhalation and intravenous anesthesia (CIVA), a prevalent general anesthesia technique, remains underexplored regarding its influence on postoperative survival in cancer surgery patients. To fill this gap, this study compares the short-term and long-term mortality of cancer surgery patients receiving CIVA versus total intravenous anesthesia (TIVA). METHODS: A retrospective cohort study was conducted at a tertiary care hospital in China, comprising 25,351 patients who underwent cancer surgery under general anesthesia between January 2014 and December 2018. The primary outcomes were short-term mortality (within 3 months) and long-term mortality (within 3 years). CIVA and TIVA were the primary exposures. Propensity score matching (PSM) was employed to adjust for confounding factors, and Cox regression models were utilized to estimate hazard ratios (HR) and 95% confidence intervals (CIs) for mortality outcomes. RESULTS: Among the 25,351 patients who underwent tumor resection, 23,790 were administered TIVA, while 1,561 received CIVA. In the 1:3 PSM cohort, 1,536 patients received CIVA, and 4,519 patients received TIVA. The Cox regression models for the 1:1, 1:2, and 1:3 PSM cohorts indicated that CIVA was associated with long-term mortality but not with short-term mortality. The multivariable Cox regression model following 1:3 PSM revealed that CIVA was associated with an increased risk of 3-year mortality (HR: 1.220; 95% CI: 1.043-1.404). CONCLUSION: Our results provided indirect evidence of potential hazard of inhaled anesthetics, even as a compound in CIVA, on long-term mortality after cancer surgery. Given the limitations of this retrospective study, further prospective work exploring the effect of anesthetic technique on mortality is urgently needed.